WO2010059119A1 - Combinaison de tert-butyl(2-{7-[2-(4-cyano-2-fluorophénoxy)éthyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}éthyl)carbamate et de certains benzofuranes antiarythmiques - Google Patents

Combinaison de tert-butyl(2-{7-[2-(4-cyano-2-fluorophénoxy)éthyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}éthyl)carbamate et de certains benzofuranes antiarythmiques Download PDF

Info

Publication number
WO2010059119A1
WO2010059119A1 PCT/SE2009/051312 SE2009051312W WO2010059119A1 WO 2010059119 A1 WO2010059119 A1 WO 2010059119A1 SE 2009051312 W SE2009051312 W SE 2009051312W WO 2010059119 A1 WO2010059119 A1 WO 2010059119A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
butyl
acceptable salts
pharmaceutically acceptable
combination product
Prior art date
Application number
PCT/SE2009/051312
Other languages
English (en)
Inventor
Charles Antzelevitch
Alexander Burashnikov
Leif Carlsson
Serge Sicouri
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of WO2010059119A1 publication Critical patent/WO2010059119A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms

Definitions

  • the term "administration in conjunction with” includes that the two components of the combination product ((I) (or pharmaceutically-acceptable salts thereof) and (II) (or pharmaceutically- acceptable salts thereof)) are administered (optionally repeatedly), either (in the case of a combined preparation) together, or (in the case of a kit of parts) sufficiently closely in time, to enable a beneficial effect for the patient, that is greater, over the course of the treatment of the relevant condition, than if either a formulation comprising (I) (or pharmaceutically-acceptable salts thereof), or a formulation comprising (II) (or pharmaceutically-acceptable salts thereof), are administered (optionally repeatedly) alone, in the absence of the other component, over the same course of treatment. Determination of whether a combination provides a greater beneficial effect in respect of, and over the course of treatment of, a particular condition, will depend upon the condition to be treated or prevented, but may be achieved routinely by the skilled person.
  • the combinations of the present invention may provide one or more of the following advantages: lower toxicity/reduced side effects with similar/improved efficacy; improved physical properties, e.g. storage stability, flow properties etc.; ease of formulation for example, reduced drug/drug incompatibility problems; reduced drug/drug interaction problems on administration, for example possible changes in metabolism of one drug caused by the effect of the other drug; improved patient compliance; improved quality of life; convenient dosing regimes; and/or lack of diminishing effects of one drug caused by the presence of the other drug.

Abstract

L'invention porte sur une combinaison de tert-butyl(2-{7-[2-(4-cyano-2-fluorophénoxy)éthyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}éthyl)carbamate(I) ou de sels pharmaceutiquement acceptables de ceux-ci et de certains benzofuranes antiarythmiques (II) ou de sels pharmaceutiquement acceptables de ceux-ci.
PCT/SE2009/051312 2008-11-21 2009-11-20 Combinaison de tert-butyl(2-{7-[2-(4-cyano-2-fluorophénoxy)éthyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}éthyl)carbamate et de certains benzofuranes antiarythmiques WO2010059119A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11668808P 2008-11-21 2008-11-21
US61/116,688 2008-11-21

Publications (1)

Publication Number Publication Date
WO2010059119A1 true WO2010059119A1 (fr) 2010-05-27

Family

ID=42198364

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2009/051312 WO2010059119A1 (fr) 2008-11-21 2009-11-20 Combinaison de tert-butyl(2-{7-[2-(4-cyano-2-fluorophénoxy)éthyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}éthyl)carbamate et de certains benzofuranes antiarythmiques

Country Status (1)

Country Link
WO (1) WO2010059119A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029018A2 (fr) * 1999-10-15 2001-04-26 Aryx Therapeutics Nouveaux composes enantiomeres pour le traitement des arythmies cardiaques et procedes d'utilisation
WO2003050102A1 (fr) * 2001-12-10 2003-06-19 Aryx Therapeutics Nouveaux composes pour le traitement de l'arythmie cardiaque, synthese et methodes d'utilisation desdits composes
WO2005123748A1 (fr) * 2004-06-15 2005-12-29 Astrazeneca Ab Nouveaux composes oxabispidine et leur utilisation dans le traitement des arythmies cardiaques
WO2006135316A1 (fr) * 2005-06-13 2006-12-21 Astrazeneca Ab Nouveaux composes d'oxabispidine pour le traitement des arythmies cardiaques
RU2292885C2 (ru) * 2004-10-28 2007-02-10 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Антиаритмическое лекарственное средство "тиодарон"

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029018A2 (fr) * 1999-10-15 2001-04-26 Aryx Therapeutics Nouveaux composes enantiomeres pour le traitement des arythmies cardiaques et procedes d'utilisation
WO2003050102A1 (fr) * 2001-12-10 2003-06-19 Aryx Therapeutics Nouveaux composes pour le traitement de l'arythmie cardiaque, synthese et methodes d'utilisation desdits composes
WO2005123748A1 (fr) * 2004-06-15 2005-12-29 Astrazeneca Ab Nouveaux composes oxabispidine et leur utilisation dans le traitement des arythmies cardiaques
RU2292885C2 (ru) * 2004-10-28 2007-02-10 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Антиаритмическое лекарственное средство "тиодарон"
WO2006135316A1 (fr) * 2005-06-13 2006-12-21 Astrazeneca Ab Nouveaux composes d'oxabispidine pour le traitement des arythmies cardiaques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRAGAKIS N. ET AL: "Efficacy and Safety of Ibutilide for cardioversion of Atrial Flutter and Fibrillation in Patients Receiving Amiodarone or Propafenone", PACE, vol. 28, September 2005 (2005-09-01), pages 954 - 960, XP003026999 *

Similar Documents

Publication Publication Date Title
JP4925074B2 (ja) ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
US8754087B2 (en) Method of treating atrial fibrillation
JPS6233204B2 (fr)
CA2249481A1 (fr) Utilisation de composes antiarythmiques dans la reduction de la mortalite post infarctus
US20110183995A1 (en) Eltoprazine for suppression of l-dopa induced dyskinesias
CA2681444A1 (fr) Ranolazine utilisee pour ameliorer la secretion d'insuline
CN113453677A (zh) 用于治疗急性心房颤动的舒卡定施用
AU2013221298A1 (en) Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
EP2280702A2 (fr) Utilisation de la dronédarone ou un sel pharmaceutiquement acceptable de celle-ci, pour la préparation d un médicament permettant la régulation du niveau de potassium dans le sang
CN101015556B (zh) 窦房结If电流抑制剂与钙抑制剂的组合以及含有它的药物组合物
EP2133075A1 (fr) Utilisation de dronédarone pour la préparation d'un médicament destiné à la prévention de la cardioversion
JP2013532728A (ja) 哺乳動物における不整脈の急性発作の終結、洞調律の回復、不整脈の再発予防及び／又は正常洞調律の維持のための医薬組成物
KR20000015805A (ko) 일산화질소 합성을 증가시키는 방법
WO2010059119A1 (fr) Combinaison de tert-butyl(2-{7-[2-(4-cyano-2-fluorophénoxy)éthyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}éthyl)carbamate et de certains benzofuranes antiarythmiques
CA2383783A1 (fr) Utilisation de bisulfonamides pour preparer des medicaments s'utilisant pour assurer la prophylaxie ou le traitement de l'hyperlipidemie
AU2009241966A1 (en) Combination of dronedarone with at least one diuretic, and therapeutic use thereof
Tafreshi et al. A review of the investigational antiarrhythmic agent dronedarone
RU2373199C2 (ru) Производные бензофурана, композиции на их основе и способы лечения аритмии сердца
AU2014231724B2 (en) S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
WO2021048412A1 (fr) Polythérapies comprenant du panobinostat pour le traitement du cholangiocarcinome
WO2010137681A1 (fr) Agent prophylactique ou thérapeutique pour maladies rétiniennes comprenant du tranilast, méthode de prévention ou de traitement de maladies rétiniennes, tranilast ou sel pharmaceutiquement acceptable de celui-ci, et utilisation de ceux-ci
WO2021048419A1 (fr) Polythérapies comprenant du tramétinib pour le traitement du cholangiocarcinome
IL298833A (en) Methods for treating or preventing chronic kidney disease
JP2002505678A (ja) 腫瘍組織を選択的に制御するための、相乗効果を有する組成物
KR20010052947A (ko) 호모시스테인 및 ｃ-반응성 단백질의 수치를 감소시키는방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09827831

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09827831

Country of ref document: EP

Kind code of ref document: A1